Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway

This article was originally published in The Pink Sheet Daily

Executive Summary

The newly proposed “expedited access” PMA program combines early and outsized interactions between reviewers and manufacturers with the promise of lightened premarket requirements for selected products – if the potential pay off to patients is large enough and postmarket controls are sufficient.

Advertisement

Related Content

Planned PMA Pathway Modeled On Existing Accelerated Programs
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices

Topics

Advertisement
UsernamePublicRestriction

Register

PS077146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel